These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 35224748)

  • 1. Development of systemic lupus erythematosus after dupilumab treatment in a case of atopic dermatitis.
    Okune M; Okiyama N; Fukuzono M; Sasaki K; Nomura T
    J Dermatol; 2022 May; 49(5):556-559. PubMed ID: 35224748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rosacea associated with dupilumab therapy.
    Heibel HD; Hendricks AJ; Foshee JP; Shi VY
    J Dermatolog Treat; 2021 Feb; 32(1):114-116. PubMed ID: 31132923
    [No Abstract]   [Full Text] [Related]  

  • 3. Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients.
    Guex-Crosier Y; Di-Lucca J; Häusermann P; Laffitte E; Saulite I; Schmid-Grendelmeier P; Schürch K; Thormann K; Simon D
    Swiss Med Wkly; 2021 Aug; 151():w30020. PubMed ID: 34495603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Facial erythema after the treatment of dupilumab in SLE patient.
    Jang DH; Lee JI; Bae JY; Jung HJ; Park MY; Ahn J
    Allergy Asthma Clin Immunol; 2020; 16():60. PubMed ID: 32944024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dupilumab-related type 1 diabetes in a patient with atopic dermatitis: a case report.
    Kurokawa Y; Oikawa Y; Shimada A; Yajima K
    Diabetol Int; 2022 Jan; 13(1):300-303. PubMed ID: 35059267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psoriasiform dermatitis during dupilumab treatment for moderate-to-severe atopic dermatitis in children.
    Parker JJ; Sugarman JL; Silverberg NB; Gonzalez ME; Ramien ML; Teng JMC; Paller AS
    Pediatr Dermatol; 2021 Nov; 38(6):1500-1505. PubMed ID: 34647354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of dupilumab in a patient with atopic dermatitis, severe asthma, and HIV infection.
    Brodska P; Panzner P; Sedlacek D; Terl M; Cetkovska P
    Dermatol Ther; 2020 Nov; 33(6):e14159. PubMed ID: 32776586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dupilumab-Associated Adverse Events During Treatment of Allergic Diseases.
    Kychygina A; Cassagne M; Tauber M; Galiacy S; Paul C; Fournié P; Simon M
    Clin Rev Allergy Immunol; 2022 Jun; 62(3):519-533. PubMed ID: 35275334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).
    de Bruin-Weller M; Thaçi D; Smith CH; Reich K; Cork MJ; Radin A; Zhang Q; Akinlade B; Gadkari A; Eckert L; Hultsch T; Chen Z; Pirozzi G; Graham NMH; Shumel B
    Br J Dermatol; 2018 May; 178(5):1083-1101. PubMed ID: 29193016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Efficacy of Dupilumab in Alopecia Areata.
    Kulkarni M; Rohan CA; Travers JB; Serrao R
    Am J Case Rep; 2022 Jun; 23():e936488. PubMed ID: 35726185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
    Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
    Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rowell Syndrome in Nigeria: Systemic Lupus Erythematosus Presenting as Recurrent Erythema Multiforme in a Young Woman.
    Akintayo RO; Olarinoye GM; Akintayo FC; Ilesanmi ON
    Acta Dermatovenerol Croat; 2019 Sep; 27(3):200-201. PubMed ID: 31542069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early and Long-Term Effects of Dupilumab Treatment on Circulating T-Cell Functions in Patients with Moderate-to-Severe Atopic Dermatitis.
    Bakker DS; van der Wal MM; Heeb LEM; Giovannone B; Asamoah M; Delemarre EM; Drylewicz J; Nierkens S; Boyman O; de Bruin-Weller MS; Thijs JL; van Wijk F
    J Invest Dermatol; 2021 Aug; 141(8):1943-1953.e13. PubMed ID: 33610558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next?
    van der Schaft J; Thijs JL; de Bruin-Weller MS; Balak DMW
    Curr Opin Allergy Clin Immunol; 2019 Aug; 19(4):341-349. PubMed ID: 31145194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two differing presentations of periocular dermatitis as a side effect of dupilumab for atopic dermatitis.
    Yamane MLM; Belsito DV; Glass LRD
    Orbit; 2019 Oct; 38(5):390-394. PubMed ID: 30628518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dupilumab for Atopic Dermatitis, a Possible Risk Factor of Juvenile Ischemic Stroke: A Case Report.
    Iwase R; Ishiguro T; Fujita K; Ishibashi S; Yokota T
    J Stroke Cerebrovasc Dis; 2020 Jun; 29(6):104763. PubMed ID: 32265139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Refractory Dupilumab-Induced Inflammatory Arthritis Treated by Upadacitinib: A 'Janus Kinase (JAK)' of All Trades.
    Cooper S; Mohamed A; Ocon A
    Cureus; 2024 Sep; 16(9):e68438. PubMed ID: 39360077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dupilumab in the treatment of severe atopic dermatitis refractory to systemic immunosuppression: case report.
    Giavina-Bianchi MH; Giavina-Bianchi P; Rizzo LV
    Einstein (Sao Paulo); 2019 Jul; 17(4):eRC4599. PubMed ID: 31291386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis.
    Guttman-Yassky E; Bissonnette R; Ungar B; Suárez-Fariñas M; Ardeleanu M; Esaki H; Suprun M; Estrada Y; Xu H; Peng X; Silverberg JI; Menter A; Krueger JG; Zhang R; Chaudhry U; Swanson B; Graham NMH; Pirozzi G; Yancopoulos GD; D Hamilton JD
    J Allergy Clin Immunol; 2019 Jan; 143(1):155-172. PubMed ID: 30194992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dupilumab for atopic dermatitis: evidence to date.
    Rodrigues MA; Nogueira M; Torres T
    G Ital Dermatol Venereol; 2019 Dec; 154(6):696-713. PubMed ID: 31210470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.